M&A seen as an elixir to ignite growth of Indian pharma

A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India.

As Indian pharmaceutical companies wake up to the prolonged timelines associated with organic growth, given the multifaceted development process, research and development (R&D) phases, and regulatory approvals, all of which collectively demand significant time and resources, M&A transactions are emerging as an appealing avenue to expedite growth, reports The Pharma Letter’s India correspondent.

As an official pointed out, M&As can lead to huge cost savings through economies of scale, streamlined operations, and supply chain optimisation, which is critical in a competitive and cost-sensitive global pharmaceutical market.